Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss current treatment approached in platinum-resistant ovarian cancer.
Back
Expanding on Treatment Trends in Platinum-Resistant Ovarian Cancer
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, break down the latest data trends in platinum-resistant ovarian cancer.
Expanding on Treatment Trends in Platinum-Resistant Ovarian Cancer
Episodes
All
All
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on final overall survival data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.
EP. 3: PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss other potential roles for mirvetuximab soravtansine in ovarian cancer.
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss updates in ovarian cancer from the 2025 SGO Annual Meeting.
Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss ongoing research and areas of potential investigation in ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
Updated SERENA-6 Data Sharpen the Debate on Early ctDNA-Guided Switching in Advanced Breast Cancer
3
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
4
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
5